Marc Voigt - Immutep CEO, Executive Director
| IMMP Stock | USD 2.03 0.04 2.01% |
CEO
Mr. Marc Voigt serves as Chief Executive Officer, Executive Director of Prima Biomed Ltd. Marc has more than 18 years of experience in the financial and biotech industry, having joined the Prima team in 2011 as the General Manager, European Operations based in Berlin, Germany. In May 2012, he became Primas Chief Business Officer and in November 2012 its Chief Financial Officer, as well as continuing to focus on its European operations. Having started his career at the Allianz Group working in pension insurances and funds, he moved to net. IPO AG, a publiclylisted boutique investment bank in Frankfurt where he was focused on IPOs and VC investments. Marc then worked for a number of years as an investment manager for a midsize VC fund based in Berlin, specializing in healthcare. He also gained considerable operational experience while serving in different management roles with Revotar Biopharmaceuticals, Caprotec Bioanalytics and Medical Enzymes AG respectfully, where he handled several successful licensing transactions and financing rounds. since 2016.
| Age | 51 |
| Tenure | 8 years |
| Address | Australia Square, Sydney, NSW, Australia, 2000 |
| Phone | 61 2 8315 7003 |
| Web | https://www.immutep.com |
Immutep Management Efficiency
The company has return on total asset (ROA) of (0.1667) % which means that it has lost $0.1667 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2621) %, meaning that it created substantial loss on money invested by shareholders. Immutep's management efficiency ratios could be used to measure how well Immutep manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/01/2024, Return On Tangible Assets is likely to drop to -0.27. In addition to that, Return On Capital Employed is likely to drop to -0.31. At this time, Immutep's Total Current Liabilities is relatively stable compared to the past year. As of 12/01/2024, Liabilities And Stockholders Equity is likely to grow to about 211.7 M, while Non Current Liabilities Total is likely to drop slightly above 1.5 M.Similar Executives
| Found 2 records | CEO Age | ||
| JD Esq | Cns Pharmaceuticals | 55 | |
| Elizabeth MBA | Ocean Biomedical | 67 | |
Management Performance
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.17 |
Immutep Ltd ADR Leadership Team
Elected by the shareholders, the Immutep's board of directors comprises two types of representatives: Immutep inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immutep. The board's role is to monitor Immutep's management team and ensure that shareholders' interests are well served. Immutep's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immutep's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frederic MD, Chief Director | ||
| Deanne LLB, General COO | ||
| Indira Naidu, Joint Secretary | ||
| Christian Mueller, Director Affairs | ||
| Shengfei Fang, F Sec | ||
| MD MSc, Chief Officer | ||
| MSc BBA, Senior Strategy | ||
| Marc Voigt, CEO, Executive Director |
Immutep Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immutep a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (13.53) % | ||||
| Current Valuation | 190.3 M | ||||
| Shares Outstanding | 145.46 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 6.27 % | ||||
| Number Of Shares Shorted | 5.13 M | ||||
| Price To Earning | (152.55) X | ||||
| Price To Book | 2.40 X |
Pair Trading with Immutep
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immutep position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immutep will appreciate offsetting losses from the drop in the long position's value.Moving together with Immutep Stock
Moving against Immutep Stock
| 0.92 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.88 | BHC | Bausch Health Companies | PairCorr |
| 0.84 | GILD | Gilead Sciences | PairCorr |
| 0.76 | GANX | Gain Therapeutics | PairCorr |
| 0.75 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Immutep could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immutep when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immutep - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immutep Ltd ADR to buy it.
The correlation of Immutep is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immutep moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immutep Ltd ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immutep can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Immutep Stock Analysis
When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.